International AIDS Vaccine Initiative

International AIDS Vaccine Initiative
Name	International AIDS Vaccine Initiative
Founded	1996
Type	Not-for-profit public-private partnership
Focus	HIV/AIDS vaccine research and development
Headquarters	New York City, United States
Key people	Mark Feinberg (President & CEO)
Website	iavi.org

International AIDS Vaccine Initiative. It is a global not-for-profit organization dedicated to accelerating the discovery and development of preventive vaccines against HIV and AIDS. Founded in 1996, it operates as a product development partnership, bridging the gap between public-sector research and private-sector development. The organization collaborates with partners in over 30 countries to advance a diverse portfolio of vaccine candidates and related biomedical innovations.

History and founding

The organization was established in 1996 by a group of visionary scientists, public health leaders, and philanthropists who recognized the critical need for a preventive vaccine to end the AIDS pandemic. Key early supporters included the Rockefeller Foundation, the Alfred P. Sloan Foundation, and the Starr Foundation. Its creation was a direct response to the perceived market failure in vaccine development for diseases predominantly affecting low-income countries, a challenge highlighted by the devastating spread of HIV in regions like Sub-Saharan Africa. The founding leadership included Seth Berkley, who served as its first CEO and later led Gavi, the Vaccine Alliance.

Mission and goals

The core mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for global use. A central goal is to make such vaccines available to all people, prioritizing populations in low- and middle-income countries most affected by the epidemic. The organization is committed to advancing the field of immunology and vaccinology through transformative science while strengthening clinical trial capacity in endemic regions. It also aims to pioneer novel biomedical interventions, such as broadly neutralizing antibodies, to complement vaccine efforts.

Scientific approach and research

The scientific strategy focuses on overcoming the unique challenges posed by HIV, including its rapid mutation rate and ability to evade the human immune system. Research emphasizes the discovery and design of immunogens capable of inducing broadly neutralizing antibodies, a key area explored at its Neutralizing Antibody Center at Scripps Research. The organization supports a broad portfolio spanning early-stage discovery, preclinical testing, and clinical trials, including work on mRNA vaccine platforms. It also investigates viral vectors and other delivery systems through partnerships with institutions like the Beth Israel Deaconess Medical Center and the University of Oxford.

Key programs and initiatives

Major programs include the Vaccine Immunology Science and Technology for Africa initiative, which builds laboratory and clinical research capacity across the continent. The Antibody Mediated Prevention trials, conducted in partnership with the HIV Vaccine Trials Network, have been pivotal in evaluating the efficacy of broadly neutralizing antibodies. The organization also leads the Advancing Translational Science initiative to accelerate the development of novel vaccine candidates. Its work extends to advocacy and policy through the Resource Tracking for HIV Prevention Research & Development project, which monitors global investment.

Partnerships and funding

It operates through an extensive network of collaborations with academic institutions, biotechnology and pharmaceutical companies, governments, and communities. Key scientific partners include the National Institutes of Health, the Bill & Melinda Gates Foundation, and the European Union. Funding is derived from a diverse mix of public donors, such as the governments of the United States, the United Kingdom, and Norway, as well as private foundations and philanthropic individuals. These partnerships are essential for sharing risks, pooling expertise, and mobilizing resources for large-scale clinical trials conducted in countries like South Africa, Zambia, and Rwanda.

Impact and achievements

The organization has played a central role in advancing the scientific understanding of HIV immunology and has contributed to several landmark studies. Its clinical research networks have enrolled thousands of volunteers in trials across Africa, Europe, and the Americas, significantly strengthening local research infrastructure. It has advanced multiple vaccine candidates into human testing, including pioneering work on mosaic immunogens and antibody-based prevention. The knowledge and technologies generated have also informed broader vaccine development efforts, including those for other pathogens like Ebola virus and SARS-CoV-2.

Challenges and future directions

Major ongoing challenges include the scientific complexity of HIV, the high cost of late-stage clinical trials, and ensuring sustainable funding for long-term research. Future directions involve deepening the integration of cutting-edge platforms like mRNA and computational design, exemplified by collaborations with Moderna and BioNTech. The organization is also focused on advancing long-acting antibody products for prevention and expanding its role in pandemic preparedness. A continued emphasis on equitable access and community engagement in trial design remains a cornerstone of its strategy to ultimately end the AIDS epidemic.

Category:Medical research organizations Category:HIV/AIDS organizations Category:Organizations established in 1996